Trending...
- Kaltra Introduces New Downward-Spraying Distribution Technology to Boost Microchannel Evaporator Performance
- Talentica Announces Winners of Multi-Agent Hackathon 2026
- Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
$RENB Collaboration with $NVDA to Employ NVIDIA AI Tech with Established GEDi CUBE as a Paradigm Shift for Early Disease Detection
LOS ANGELES - PennZone -- Developing AI and Biotechnology Platforms for Early Diagnosis, Better-Targeted Treatments and Drug Discovery.
Pioneer Leader in Cancer Diagnostics and Therapeutics Powered by Artificial Intelligence (AI).
$15 Million in New Equity Committed to accelerate Focus on Revolutionizing Healthcare via the Company's Established Strategies.
2025 Shareholder Update Issued from CEO.
Plans to Attend American Association for Cancer Research (AACR), The First and Largest Cancer Research Organization, Annual Meeting in April, 2025.
Funding Approval of LUMINA Minimal Residual Disease Detection Platform for Lung Cancer Harnessing Multi-omics Biomarkers and AI.
Entered Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection.
Plans to Establish the Renovaro GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's Certified AI Healthcare Cloud Solutions.
Renovaro, Inc. (Stock Symbol: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development.
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
$15 Million in New Equity Committed
On February 26th RENB announced that it has $15 million in additional equity committed at a price per share of $1.00 and one privately placed cash warrant exercisable at $1.50 with a one year term.
More on The PennZone
David Weinstein, Chief Executive Officer of Renovaro, commented, "We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery."
Shareholder Letter and Corporate Update
On January 7th RENB issued a letter to shareholders from Chief Executive Officer David Weinstein. The letter contained the following commentary:
Dear Shareholders,
We have identified three areas as mission critical for building the point of care cancer detection, personalized therapy and vaccine business are: we need to acquire large amounts of data, build the business of clinical decision support for oncologists, and monetize our AI though building and licensing predictive models for drug repurposing and our cancer vaccine. We are meeting these three challenges through the acquisition of Predictive Oncology.
RENB recently signed a binding letter of intent to acquire Predictive Oncology (Stock Symbol: POAI) that will provide with a tremendous company-owned database consisting of 150,000 frozen / live tumor samples, 20 years of drug response data, 40,000 FFPE tissue blocks, 200,000 pathology slides and digital library, and a fully certified CLIA laboratory. RENB plans to commercialize Predictive's clinical support test that assists oncologists in selecting the best therapy for their patients, and deploy their multi-omic AI system for drug discovery known as PEDAL (Patient-centric Discovery by Active Learning), a platform that combines AI technology, drug response data, and a large biobank of tumor samples to predict how different tumors will respond to various drugs.
When RENB acquired GEDiCube, the rationale was that these two business segments were synergistic. This remains a core value proposition but for synergies to materialize requires structured collaboration between the two verticals: AI cancer detection and genetically enhanced cancer vaccines. There are two business developments that RENB is pursuing.
Identifying a whole genome sequencer that can serve as the front end of RENB point of care cancer detection platform.
GEDiCube to deploy its AI/ML analysis to discover more genes and factors that can be deployed in RENB Dendritic Cancer Cell Vaccine (DCCV). Incorporating these new discoveries into RENB patent filings will build shareholder value by ringfencing the DCCV platform and providing the ability to partner or license specific cancer applications. This has the potential to enhance the core three elements RENB infuses into DCCV now, allowing it to become specific for cancer types, and ultimately be available as an off the shelf solution. In the future this could facilitate early cancer detection in a doctor's office followed by the treatment of a patient with our vaccine. To gain exposure for our DCCV and generate business development RENB will be attending the American Association for Cancer Research (AACR), the first and largest cancer research organization, Annual Meeting in April 2025.
More on The PennZone
To make its AI/ML powered early cancer detection tests a reality, RENB requires two vital components: the latest superpods to achieve the speed necessary to run trillions of calculations, and critical data and sample sets. RENB announced in late December 2024, a strategic collaboration with Nebul (www.nebul.com) that will provide that power. Additionally, Nebul is focused on healthcare and is ISO certified. The company has received a grant for the Lumina project that aims to deliver an advanced Minimal Residual Disease (MRD) detection platform for non-small cell lung cancer (NSCLC). This project provides RENB with 100 samples for immediate analysis followed by an additional 200 samples as they are generated and provides critical data.
Maurice van Tilburg, RENB Chairman, has decided to join full time as the CEO of the AL/ML subsidiary, GEDiCube. Renovaro management, including Mr. van Tilburg.
Further strengthening the management team, RENB has brought Nathen Fuentes on board as CFO. On the corporate front, NASDAQ notified that the company is now in good standing.
For more information on $RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/
Media Contact
Company Name: Renovaro Inc. (Stock Symbol: RENB)
Contact Person: David Weinstein, CEO
Company Websites: www.renovarobio.com and https://www.compasslivemedia.com/renb/
Email: ir@renovarobio.com
Phone: 732-780-5036
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Pioneer Leader in Cancer Diagnostics and Therapeutics Powered by Artificial Intelligence (AI).
$15 Million in New Equity Committed to accelerate Focus on Revolutionizing Healthcare via the Company's Established Strategies.
2025 Shareholder Update Issued from CEO.
Plans to Attend American Association for Cancer Research (AACR), The First and Largest Cancer Research Organization, Annual Meeting in April, 2025.
Funding Approval of LUMINA Minimal Residual Disease Detection Platform for Lung Cancer Harnessing Multi-omics Biomarkers and AI.
Entered Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection.
Plans to Establish the Renovaro GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's Certified AI Healthcare Cloud Solutions.
Renovaro, Inc. (Stock Symbol: RENB) aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development.
RENB RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective.
RENB RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
$15 Million in New Equity Committed
On February 26th RENB announced that it has $15 million in additional equity committed at a price per share of $1.00 and one privately placed cash warrant exercisable at $1.50 with a one year term.
More on The PennZone
- York Entrepreneur Launches AI Training to Help Small Businesses Navigate the AI Revolution
- Cancun International Airport Prepares for Record Travel Surge Ahead of Spring Break, Summer, and the 2026 High Season
- $167 Billion Pharma R&D Market Largely Untapped by AI Creates Major Growth Runway for KALA Bios Data-Sovereign AI Strategy: N A S D A Q: KALA
- Lighthouse Tech Awards Recognize Top HR Technology Providers for 2026
- ADB Selects OneVizion to Advance Field Execution and Infrastructure Program Management
David Weinstein, Chief Executive Officer of Renovaro, commented, "We believe this new capital now enables the company to accelerate our focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery."
Shareholder Letter and Corporate Update
On January 7th RENB issued a letter to shareholders from Chief Executive Officer David Weinstein. The letter contained the following commentary:
Dear Shareholders,
We have identified three areas as mission critical for building the point of care cancer detection, personalized therapy and vaccine business are: we need to acquire large amounts of data, build the business of clinical decision support for oncologists, and monetize our AI though building and licensing predictive models for drug repurposing and our cancer vaccine. We are meeting these three challenges through the acquisition of Predictive Oncology.
RENB recently signed a binding letter of intent to acquire Predictive Oncology (Stock Symbol: POAI) that will provide with a tremendous company-owned database consisting of 150,000 frozen / live tumor samples, 20 years of drug response data, 40,000 FFPE tissue blocks, 200,000 pathology slides and digital library, and a fully certified CLIA laboratory. RENB plans to commercialize Predictive's clinical support test that assists oncologists in selecting the best therapy for their patients, and deploy their multi-omic AI system for drug discovery known as PEDAL (Patient-centric Discovery by Active Learning), a platform that combines AI technology, drug response data, and a large biobank of tumor samples to predict how different tumors will respond to various drugs.
When RENB acquired GEDiCube, the rationale was that these two business segments were synergistic. This remains a core value proposition but for synergies to materialize requires structured collaboration between the two verticals: AI cancer detection and genetically enhanced cancer vaccines. There are two business developments that RENB is pursuing.
Identifying a whole genome sequencer that can serve as the front end of RENB point of care cancer detection platform.
GEDiCube to deploy its AI/ML analysis to discover more genes and factors that can be deployed in RENB Dendritic Cancer Cell Vaccine (DCCV). Incorporating these new discoveries into RENB patent filings will build shareholder value by ringfencing the DCCV platform and providing the ability to partner or license specific cancer applications. This has the potential to enhance the core three elements RENB infuses into DCCV now, allowing it to become specific for cancer types, and ultimately be available as an off the shelf solution. In the future this could facilitate early cancer detection in a doctor's office followed by the treatment of a patient with our vaccine. To gain exposure for our DCCV and generate business development RENB will be attending the American Association for Cancer Research (AACR), the first and largest cancer research organization, Annual Meeting in April 2025.
More on The PennZone
- Memelinked Social Media powered by cryptocurrency launching July 2026
- Actor Phillip Steward Featured on The Industry Podcast with James Winborn
- Seven-Year-Old Toronto Dancer Julianna Selivanov Wins Nine Medals at Quebec Championship and Reaches Finals at UK Dance Festival
- Pa. Department of Environmental Protection Approves Keystone Consulting Engineers as a Qualified Professional in its SPEED Program
- Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
To make its AI/ML powered early cancer detection tests a reality, RENB requires two vital components: the latest superpods to achieve the speed necessary to run trillions of calculations, and critical data and sample sets. RENB announced in late December 2024, a strategic collaboration with Nebul (www.nebul.com) that will provide that power. Additionally, Nebul is focused on healthcare and is ISO certified. The company has received a grant for the Lumina project that aims to deliver an advanced Minimal Residual Disease (MRD) detection platform for non-small cell lung cancer (NSCLC). This project provides RENB with 100 samples for immediate analysis followed by an additional 200 samples as they are generated and provides critical data.
Maurice van Tilburg, RENB Chairman, has decided to join full time as the CEO of the AL/ML subsidiary, GEDiCube. Renovaro management, including Mr. van Tilburg.
Further strengthening the management team, RENB has brought Nathen Fuentes on board as CFO. On the corporate front, NASDAQ notified that the company is now in good standing.
For more information on $RENB visit: http://www.renovarobio.com and https://compasslivemedia.com/renb/
Media Contact
Company Name: Renovaro Inc. (Stock Symbol: RENB)
Contact Person: David Weinstein, CEO
Company Websites: www.renovarobio.com and https://www.compasslivemedia.com/renb/
Email: ir@renovarobio.com
Phone: 732-780-5036
Home Country: United States
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
Filed Under: Business
0 Comments
Latest on The PennZone
- P-Wave Classics to publish Robert Bage's Hermsprong in three volumes, beginning 12 May
- Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
- Kilmaine Saints to Record Live Album at XL Live
- CCHR: While Damaging Antipsychotics Win Approval, Proven Non-Drug Alternatives Remain Ignored
- Arcuri Group Announces Long‑Term Partnership with WakeMed Health & Hospitals to Deliver Situational Awareness and De‑escalation Training
- KDG Announces Acquisition of Square Foot Consultants, Expanding Business and Technology Expertise
- Colonial Nissan Service Named Top 5 Auto Repair in Feasterville-Trevose for 2025
- At 25, She Became One of the Youngest AAPI Female Founders to Win One of the World's Most Prestigious Design Awards for a Lamp That Makes You Smile
- Juego Studios Extends Full-Cycle Game Development & Outsourcing Capabilities to the UAE Market
- VENUS Goes Live on CATEX Exchange As UK Financial Ltd Activates The Premier Division Of The Maya Meme's League
- Atlanta Tech Founder Seeks Clarity on Intellectual Property and Innovation Policy
- Purple Heart Recipient Honored by Hall of Fame Son In Viral Tribute Sparking National Conversation on Service Fatherhood, Healing and Legacy
- Maronda Homes Leverages Power of AI to Automate, Accelerate Home Warranty Claims Process
- ATS (The Athletic Trainer System) Releases comprehensive student health features
- Amicly Launches as a Safety-First Social App Designed to Help People Build Real, Meaningful Friendships
- Primeindexer Google indexing platform launched by SEO Danmark APS
- Kaltra Introduces New Downward-Spraying Distribution Technology to Boost Microchannel Evaporator Performance
- Talentica Announces Winners of Multi-Agent Hackathon 2026
- Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth
- Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX